Holen Sie sich die Stockscreener-App
39.65
0.25%
-0.10
Handel nachbörslich:
39.65
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history - Yahoo Finance UK
Tyra Biosciences, Inc. (TYRA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and history - Yahoo Finance Australia
Spyre Therapeutics, Inc. (SYRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
A quarterly stock award gives director Fox 308 shares of Edgewise Therapeutics (EWTX). - stocktitan.net
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Edgewise Therapeutics Jumps As EDG-7500 Data Fuels Bullish Target Hike - StocksToTrade
Edgewise Therapeutics Stock Jumps As JPMorgan Hikes Target - timothysykes.com
Edgewise Therapeutics Stock Rises as JPMorgan Lifts Price Target - timothysykes.com
Edgewise Therapeutics Stock Rises as JPMorgan Lifts Price Target - Timothy Sykes
Trading Systems Reacting to (EWTX) Volatility - Stock Traders Daily
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Four new employees receive stock awards from Edgewise - Stock Titan
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $59 - Moomoo
The Technical Signals Behind (EWTX) That Institutions Follow - Stock Traders Daily
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 - PR Newswire
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results - Eastern Progress
Edgewise Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
EWTX Maintains Overweight Rating -- Price Target Raised to $60 - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edgewise Therapeutics (NASDAQ:EWTX) Stock - MarketBeat
Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising SpendHas The Bull Case Changed? - simplywall.st
Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising SpendHas The Bull Case Changed? - simplywall.st
Edgewise (EWTX) Results and Estimates: The Available Earnings Metric Delivers a Miss in the Available Record; Price Reaction: The Stock Ends Up 0.16% in Latest TradingConsensus Miss Rate - vinanet.vn
Edgewise Therapeutics: Servier Deal Creates A Self-Funded Cardiovascular Platform (EWTX) - Seeking Alpha
Edgewise Therapeutics (EWTX) corrects CFO option grant price - Stock Titan
Edgewise Therapeutics (EWTX) corrects CMO’s 65K option grant price - Stock Titan
Edgewise Therapeutics (EWTX) sets GC option price at $43.56 - Stock Titan
Edgewise Therapeutics (EWTX) gives CSO 65K options at $43.56 - Stock Titan
Edgewise (NASDAQ: EWTX) CBO gets 100K options vesting from 2026 - Stock Titan
69,441 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Persistent Asset Partners Ltd - MarketBeat
44,466 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by GSA Capital Partners LLP - MarketBeat
Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich - Sahm
Edgewise Therapeutics (EWTX) Gains 2.29% to $44.17, Maintains Upside MomentumStock Surge Alerts - vinanet.vn
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock By Investing.com - Investing.com India
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CSO Alan Russell sells $258k in stock - Investing.com
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock - Investing.com
Edgewise Therapeutics CSO Alan Russell sells $258k in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock - Investing.com
Edgewise Therapeutics general counsel Moore sells $219,822 in shares - Investing.com
Edgewise Therapeutics CBO sells $223k in shares for tax obligations - Investing.com
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock By Investing.com - Investing.com Australia
Edgewise Therapeutics general counsel Moore sells $219,822 in shares By Investing.com - Investing.com Australia
Edgewise Therapeutics general counsel Moore sells $219,822 in shares By Investing.com - Investing.com Australia
Edgewise Therapeutics general counsel Moore sells $219,822 in shares By Investing.com - Investing.com South Africa
Edgewise Therapeutics CSO Alan Russell sells $258k in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics general counsel Moore sells $219,822 in shares By Investing.com - Investing.com Canada
Edgewise Therapeutics CSO Alan Russell sells $258k in stock By Investing.com - Investing.com Nigeria
0.83%
6.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):